{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 69 of 74', 'Table 2 Adverse reactions reported in the integrated safety population of', 'trametinib monotherapy (n=329)', 'System Organ Class', 'Frequency (all grades)', 'Adverse Reactions', 'Infections and infestation', 'Common', 'Folliculitis', 'Paronychia', 'Cellulitis', 'Rash pustular', 'Blood and lymphatic', 'Common', 'Anaemia', 'system', 'disorders', 'Immune system disorders', 'Common', 'Hypersensitivity', 'Metabolism and nutrition', 'Common', 'Dehydration', 'disorders', 'Eye disorders', 'Common', 'Vision blurred', 'Periorbital oedema', 'Visual impairment', 'Uncommon', 'Chorioretinopathy', 'Papilloedema', 'Retinal detachment', 'Retinal vein occlusion', 'Cardiac disorders', 'Common', 'Left ventricular', 'dysfunction', 'Ejection fraction decreased', 'Bradycardia', 'Uncommon', 'Cardiac failure', 'Vascular disorders', 'Very common', 'Hypertension', 'Haemorrhage', 'Common', 'Lymphoedema', 'Respiratory, thoracic and', 'Very common', 'Cough', 'mediastinal disorders', 'Dyspnoea', 'Common', 'Pneumoniti', 'Uncommon', 'Interstitial lung disease', 'Gastrointestinal disorders', 'Very common', 'Diarrhoea', 'Nausea', 'Vomiting', 'Constipation', 'Abdominal pain', 'Dry mouth', 'Common', 'Stomatitis', 'Uncommon', 'Gastrointestinal', 'perforation', 'Colitis', 'Skin and subcutaneous', 'Very common', 'Rash', 'disorders', 'Dermatitis acneiform', 'Dry skin', 'Pruritus', 'Alopecia', 'Common', 'Erythema', 'Palmar-plantar', 'erythrodysaesthesia', 'syndrome', 'Skin fissures', 'Skin chapped', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 70 of 74', 'Musculoskeletal and', 'Uncommon', 'Rhabdomyolysis', 'connective', 'tissue disorders', 'General disorders and', 'Very Common', 'Fatigue', 'administration site', 'Oedema peripheral', 'conditions', 'Pyrexia', 'Common', 'Face oedema', 'Mucosal inflammation', 'Asthenia', 'Investigations', 'Very common', 'Aspartate', 'aminotransferase', 'increased', 'Common', 'Alanine aminotransferase', 'increased', 'Blood alkaline', 'phosphatase increased', 'Blood creatine', 'phosphokinase increased', 'a May present with symptoms such as fever, rash, increased liver transaminases,', 'and visual disturbances', 'b', 'Events include but are not limited to: epistaxis, haematochezia, gingival bleeding,', 'haematuria, and rectal, haemorrhoidal, gastric, vaginal, conjunctival, intracranial and', 'post procedural haemorrhage.', 'Table 3 Adverse reactions reported in the integrated safety population of', 'dabrafenib in combination with trametinib (n=641)', 'System Organ Class', 'Frequency (all grades)', 'Adverse Reactions', 'Infections and infestations', 'Very common', 'Urinary tract infection', 'Nasopharyngitis', 'Common', 'Cellulitis', 'Folliculitis', 'Paronychia', 'Rash pustular', 'Neoplasms benign,', 'Common', 'Cutaneous squamous cell', 'malignant', 'carcinomaa', 'and unspecified (incl cysts', 'Papillomab', 'and', 'Seborrhoeic keratosis', 'polyps)', 'Uncommon', 'New primary melanoma', 'Acrochordon (skin tags)', 'Blood and lymphatic', 'Very common', 'Neutropenia', 'system', 'Common', 'Anaemia', 'disorders', 'Thrombocytopenia', 'Leukopenia', 'Immune system disorders', 'Uncommon', 'Hypersensitivity', 'Metabolism and nutrition', 'Very common', 'Decreased appetite', 'disorders', 'Common', 'Dehydration', 'Hyponatraemia', 'Hypophosphataemia', 'Hyperglycaemia', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}